Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy

Bone Marrow Transplantation

Volumn 38, Issue 4, 2006, Pages 299-303

  Lee, H J ^a   Oran, B ^b   Saliba, R M ^b   Couriel, D M ^b   Shin, K ^b   Massey, P ^b   Neumann, J ^b   de Lima, M ^b   Champlin, R ^b   Giralt, S ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; PENTOSTATIN; STEROID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BACTERIAL INFECTION; CATARACT; CONTROLLED STUDY; CORTICOSTEROID INDUCED MYOPATHY; DEPRESSION; DISEASE SEVERITY; DRUG MEGADOSE; EDEMA; FEMALE; FREQUENCY ANALYSIS; GASTRITIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MYCOSIS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEROID THERAPY; SURVIVAL TIME; VIRUS INFECTION;

ACUTE DISEASE; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MUSCULAR DISEASES; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; STEROIDS;

EID: 33747065225     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705435     Document Type: Article

References (34)

1. Thomas ED. Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases. J Clin Oncol 1983; 1: 517-531.
2. Antin JH. Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
3. Ferrara J, Deeg HJ. Graft versus host disease. N Engl J Med 1991; 324: 667-674.
4. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD et al. Cyclosporine, methotrexate, and prednisone Compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225-1230.
5. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
6. Ruutu T, Hermans J, van Biezen A, Niederwieser D, Gratwohl A, Apperley JF. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 22: 614-615.
7. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764.
8. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestation. Johns Hopkins Med J 1932; 50: 137.
9. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997; 48: 1234-1238.
10. Afifi AK, Bergman RA, Harvey JC. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968; 123: 158-173.
11. Heinemann AW, Linacre JM, Wright BD, Hamilton BB, Granger C. Prediction of rehabilitation outcomes with disability measures. Arch Phys Med Rehabil 1994; 75: 133-143.
12. Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function, 4th edn. Williams & Wilkins: Baltimore, 1993.
13. Linacre JM, Heinemann AW, Wright BD, Granger CV, Hamilton BB. The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil 1994; 75: 127-132.
14. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43.
15. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-963.
16. Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB, Ramsay NK. Prednisone therapy for acute graft-versus host disease: Short- versus long-term treatment. A prospective randomized trial. Transplantation 1993; 56: 577-580.
17. Hamon MD, Gale RF, Macdonald ID, Smith OP, Collis CH, Skeggs DB. Incidence of cataracts after single fraction total body irradiation: The role of steroids and graft versus host disease. Bone Marrow Transplant 1993; 12: 233-236.
18. Hardie IR, Matsunami C, Hilton A. Ocular complications in renal transplant recipients. Transplant Proc 1992; 24: 177.
19. Pai RP, Mitchell P, Chow VC. Post-transplant cataract: Lesson from kidney-pancreas transplantation. Transplantation 2000; 69: 1108.
20. Bray LC, Carey PJ, Proctor SJ, Evans RG, Hamilton PJ. Ocular complications of bone marrow transplantation. Br J Ophthalmol 1991; 75: 611-614.
21. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci (London) 1999; 96: 513-523.
22. Ullrich S, Berchtold S, Ranta F, Ris F, Rosler M, Gerlach U et al. Serum- and glucocorticoid-inducible kinase 1 (SGK 1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005; 54: 1090-1099.
23. Raul Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998; 29: 259-262.
24. Jindal RM, Hjelmesaeth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70 (Suppl 11): 58.
25. Shapiro R, Scantlebury VP, Jordan ML. Reversibility of tacrolimus-induced posttransplant diabetes: An illustrative case and review of the literature. Transplant Proc 1997; 10: 760.
26. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545.
27. Midtvedt KN, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation 1998; 70 (11 Suppl): 64.
28. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000; 59106: 651-656.
29. Renold AE, Haydar NA, Reddy WJ, Goldfien A, St Marc JR, Laidlaw JC. Biological effects of fluorinated derivatives of hydrocortisone and progesterone in man. Ann NY Acad Sci 1955; 61: 582 590.
30. Thorn GW, Renold AE, Morse WI, Goldfien A, Reddy WJ. Highly potent adrenal cortical steroids: Structure and biologic activity. Ann Intern Med 1955; 43: 979-1000.
31. Price SR, Du JD, Bailey JL, Mitch WE. Molecular mechanisms regulating protein turnover in muscle. Am J Kidney Dis 2001; 37 (1 Suppl 2): S 112-S 114.
32. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J et al. Corticosteroid myopathy: A clinical and pathological study Clin Endocrinol (Oxford) 1983; 18: 155-166.
33. Bielefeld P. Actualites sur la myopathie cortisonique. La Revue Med Interne 1996; 17: 255.
34. Shee CD. Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 1990; 84: 229-233.